Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001764013-25-000163
Filing Date
2025-12-19
Accepted
2025-12-19 16:05:25
Documents
2
Period of Report
2025-12-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1766178313.html 4  
1 FORM 4 wk-form4_1766178313.xml 4 6281
2 EX-24.1 immunovant-section16poaxch.htm EX-24.1 48522
  Complete submission text file 0001764013-25-000163.txt   56368
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Issuer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DERMAVANT SCIENCES, INC. 2398 E. CAMELBACK ROAD, SUITE 1060 PHOENIX AZ 85016
Business Address
Van Tuyl Christopher (Reporting) CIK: 0001779707 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38906 | Film No.: 251587509